Stage IIB-IVB cervical adenocarcinoma: Prognostic factors and survival

Jayanthi S. Lea, Ellen E. Sheets, Robert M. Wenham, Linda R. Duska, Robert L. Coleman, David S. Miller, John O. Schorge

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective. The incidence of cervical adenocarcinoma is increasing relative to squamous cell carcinoma and all cervical cancers. Few reports have described the outcome of patients with advanced cervical adenocarcinoma. The purpose of this study was to determine the prognostic factors and survival for patients with stage IIB-IVB disease. Methods. Institutional Review Board approval was obtained to perform a computerized search of all women diagnosed with cervical adenocarcinoma at our three institutions between 1982 and 2000. Medical records were retrospectively reviewed. Clinical follow-up was obtained from the SGO database and tumor registry and via correspondence with health care providers. Statistical analysis was performed using logistic regression for clinical variables and the log-rank test to compare Kaplan-Meier survival estimates. Results. Eighty-three women with FIGO stage IIB-IVB cervical adenocarcinoma were identified. The median patient age was 53 years (range, 22-88). The median follow-up of 17 (20%) surviving patients was 33 months (range, 6-147); 66 (80%) died during the study interval. Stage IIB disease, young patient age, and grade 1 histology were independent variables having a favorable impact on survival (each P < 0.02). Stage IIB patients (n = 41) were more likely to be alive at 2 (64% vs 8%) and 5 years (30% vs 0%) than women with stage IIIA-IVB disease (n = 42; P < 0.01). Conclusions. Women diagnosed with advanced stage cervical adenocarcinoma have a poor prognosis. Prospective, multicenter trials of platinum-based chemoradiation or other novel therapies are urgently needed in the treatment of this highly lethal disease.

Original languageEnglish (US)
Pages (from-to)115-119
Number of pages5
JournalGynecologic Oncology
Volume84
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Adenocarcinoma
Survival
Research Ethics Committees
Kaplan-Meier Estimate
Platinum
Uterine Cervical Neoplasms
Health Personnel
Multicenter Studies
Medical Records
Registries
Squamous Cell Carcinoma
Histology
Logistic Models
Databases
Incidence
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Lea, J. S., Sheets, E. E., Wenham, R. M., Duska, L. R., Coleman, R. L., Miller, D. S., & Schorge, J. O. (2002). Stage IIB-IVB cervical adenocarcinoma: Prognostic factors and survival. Gynecologic Oncology, 84(1), 115-119. https://doi.org/10.1006/gyno.2001.6473

Stage IIB-IVB cervical adenocarcinoma : Prognostic factors and survival. / Lea, Jayanthi S.; Sheets, Ellen E.; Wenham, Robert M.; Duska, Linda R.; Coleman, Robert L.; Miller, David S.; Schorge, John O.

In: Gynecologic Oncology, Vol. 84, No. 1, 2002, p. 115-119.

Research output: Contribution to journalArticle

Lea, JS, Sheets, EE, Wenham, RM, Duska, LR, Coleman, RL, Miller, DS & Schorge, JO 2002, 'Stage IIB-IVB cervical adenocarcinoma: Prognostic factors and survival', Gynecologic Oncology, vol. 84, no. 1, pp. 115-119. https://doi.org/10.1006/gyno.2001.6473
Lea, Jayanthi S. ; Sheets, Ellen E. ; Wenham, Robert M. ; Duska, Linda R. ; Coleman, Robert L. ; Miller, David S. ; Schorge, John O. / Stage IIB-IVB cervical adenocarcinoma : Prognostic factors and survival. In: Gynecologic Oncology. 2002 ; Vol. 84, No. 1. pp. 115-119.
@article{1c0bbdf42b1f478d841d96ddf560dbdf,
title = "Stage IIB-IVB cervical adenocarcinoma: Prognostic factors and survival",
abstract = "Objective. The incidence of cervical adenocarcinoma is increasing relative to squamous cell carcinoma and all cervical cancers. Few reports have described the outcome of patients with advanced cervical adenocarcinoma. The purpose of this study was to determine the prognostic factors and survival for patients with stage IIB-IVB disease. Methods. Institutional Review Board approval was obtained to perform a computerized search of all women diagnosed with cervical adenocarcinoma at our three institutions between 1982 and 2000. Medical records were retrospectively reviewed. Clinical follow-up was obtained from the SGO database and tumor registry and via correspondence with health care providers. Statistical analysis was performed using logistic regression for clinical variables and the log-rank test to compare Kaplan-Meier survival estimates. Results. Eighty-three women with FIGO stage IIB-IVB cervical adenocarcinoma were identified. The median patient age was 53 years (range, 22-88). The median follow-up of 17 (20{\%}) surviving patients was 33 months (range, 6-147); 66 (80{\%}) died during the study interval. Stage IIB disease, young patient age, and grade 1 histology were independent variables having a favorable impact on survival (each P < 0.02). Stage IIB patients (n = 41) were more likely to be alive at 2 (64{\%} vs 8{\%}) and 5 years (30{\%} vs 0{\%}) than women with stage IIIA-IVB disease (n = 42; P < 0.01). Conclusions. Women diagnosed with advanced stage cervical adenocarcinoma have a poor prognosis. Prospective, multicenter trials of platinum-based chemoradiation or other novel therapies are urgently needed in the treatment of this highly lethal disease.",
author = "Lea, {Jayanthi S.} and Sheets, {Ellen E.} and Wenham, {Robert M.} and Duska, {Linda R.} and Coleman, {Robert L.} and Miller, {David S.} and Schorge, {John O.}",
year = "2002",
doi = "10.1006/gyno.2001.6473",
language = "English (US)",
volume = "84",
pages = "115--119",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Stage IIB-IVB cervical adenocarcinoma

T2 - Prognostic factors and survival

AU - Lea, Jayanthi S.

AU - Sheets, Ellen E.

AU - Wenham, Robert M.

AU - Duska, Linda R.

AU - Coleman, Robert L.

AU - Miller, David S.

AU - Schorge, John O.

PY - 2002

Y1 - 2002

N2 - Objective. The incidence of cervical adenocarcinoma is increasing relative to squamous cell carcinoma and all cervical cancers. Few reports have described the outcome of patients with advanced cervical adenocarcinoma. The purpose of this study was to determine the prognostic factors and survival for patients with stage IIB-IVB disease. Methods. Institutional Review Board approval was obtained to perform a computerized search of all women diagnosed with cervical adenocarcinoma at our three institutions between 1982 and 2000. Medical records were retrospectively reviewed. Clinical follow-up was obtained from the SGO database and tumor registry and via correspondence with health care providers. Statistical analysis was performed using logistic regression for clinical variables and the log-rank test to compare Kaplan-Meier survival estimates. Results. Eighty-three women with FIGO stage IIB-IVB cervical adenocarcinoma were identified. The median patient age was 53 years (range, 22-88). The median follow-up of 17 (20%) surviving patients was 33 months (range, 6-147); 66 (80%) died during the study interval. Stage IIB disease, young patient age, and grade 1 histology were independent variables having a favorable impact on survival (each P < 0.02). Stage IIB patients (n = 41) were more likely to be alive at 2 (64% vs 8%) and 5 years (30% vs 0%) than women with stage IIIA-IVB disease (n = 42; P < 0.01). Conclusions. Women diagnosed with advanced stage cervical adenocarcinoma have a poor prognosis. Prospective, multicenter trials of platinum-based chemoradiation or other novel therapies are urgently needed in the treatment of this highly lethal disease.

AB - Objective. The incidence of cervical adenocarcinoma is increasing relative to squamous cell carcinoma and all cervical cancers. Few reports have described the outcome of patients with advanced cervical adenocarcinoma. The purpose of this study was to determine the prognostic factors and survival for patients with stage IIB-IVB disease. Methods. Institutional Review Board approval was obtained to perform a computerized search of all women diagnosed with cervical adenocarcinoma at our three institutions between 1982 and 2000. Medical records were retrospectively reviewed. Clinical follow-up was obtained from the SGO database and tumor registry and via correspondence with health care providers. Statistical analysis was performed using logistic regression for clinical variables and the log-rank test to compare Kaplan-Meier survival estimates. Results. Eighty-three women with FIGO stage IIB-IVB cervical adenocarcinoma were identified. The median patient age was 53 years (range, 22-88). The median follow-up of 17 (20%) surviving patients was 33 months (range, 6-147); 66 (80%) died during the study interval. Stage IIB disease, young patient age, and grade 1 histology were independent variables having a favorable impact on survival (each P < 0.02). Stage IIB patients (n = 41) were more likely to be alive at 2 (64% vs 8%) and 5 years (30% vs 0%) than women with stage IIIA-IVB disease (n = 42; P < 0.01). Conclusions. Women diagnosed with advanced stage cervical adenocarcinoma have a poor prognosis. Prospective, multicenter trials of platinum-based chemoradiation or other novel therapies are urgently needed in the treatment of this highly lethal disease.

UR - http://www.scopus.com/inward/record.url?scp=0036144381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036144381&partnerID=8YFLogxK

U2 - 10.1006/gyno.2001.6473

DO - 10.1006/gyno.2001.6473

M3 - Article

C2 - 11748986

AN - SCOPUS:0036144381

VL - 84

SP - 115

EP - 119

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -